Dendreon vs Pharmexa - 500 Beiträge pro Seite

[BrauchGeld]

Warum eine Dendreon kaufen wenn ich für weniger geld eine qualitativ bessere aktie bekomme ?
Pharmexa ist ein dänisches unternehmen das auch im bereich Krebs vaccine tätig ist und besitzt ebenfalls ein Phase III (Pancreatic Cancer) kandidat .
Pharmexa hat eine wesentlich bessere pipeline eine viel zu niedrige marktkap im vergleich zu Dendreon .


Mehr Infos zu Pharmexa findet ihr in der Präsentation .

Pharmexa (PHARMX.CO)

Marktkap: 105 mio€
Cash: 25 mio€
Kurs: 2,45 €

Präsentation April 2007:


Pipeline:


Homepage:
http://www.pharmexa.com/site.asp?p=23

Pharmexa starts pivotal phase III trial in the United States

The FDA has approved Pharmexas IND to start the PrimoVax trial in the United States. Pharmexa expects the first American pancreas cancer patient to be treated with GV1001 in a few weeks.

PrimoVax is a pivotal phase III trial testing the peptide vaccine GV1001 in patients with non-resectable pancreatic cancer. According to the plan the trial will enrol a total of 520 patients with pancreatic cancer. The trial started in the fall of 2006 in Europe and Australia and has so far enrolled approximately 100 patients from 60 centres. In Denmark, the trial is running at the university hospitals in Herlev, Odense and Århus. With the approval from FDA Pharmexa expects to open an additional 20 centres in the United States before the end of 2007. The first US centre is expected to be opened in California in a few weeks.

Pharmexa's CEO, Jakob Schmidt says: "We regard FDAs acceptance of the IND as a stamp of approval. If GV1001 performs as well in phase III as in previous clinical trials, I expect that we will be able to apply for registration of the product both in the United States and Europe in 2009. That is why we consider the PrimoVax trial pivotal."

GV1001 already has Orphan Drug status in pancreatic cancer both in the United States and Europe.




------------

Dendreon (DNDN)

Marktkap: 572,6 mio€
Cash: 57 mio€
Kurs: 6,85 €

Pipeline:
http://www.dendreon.com/dndn/pipeline

[BrauchGeld]

Präsentation April 2007:

http://www.pharmexa.com/webtop/webedit/images/common-doc/Pha…

[BrauchGeld]

Pharmexa ist aktuell auf der suche nach einem Partner für GV1001 .

GV1001 results in pancreatic cancer published in the British Journal of Cancer

Summary: Clinical results from a Phase I/II study of GV1001 in pancreatic cancer have now been published in the British Journal of Cancer (BJC).

Pharmexa has previously announced top line data from the Phase I/II trial of GV1001 in pancreatic cancer. The recently published article in BJC describes the data in further detail. As announced previously, the study found the telomerase vaccine GV1001 to be safe and immunogenic.

Survival data from the Phase I/II trial indicate that induction of an immune response is correlated with prolonged survival. The observed median survival was 7.2 months for the responders and 2.9 months for the non-responders, giving a statistically significant p value of 0.001.

The results also showed a significant increase in survival in the intermediate dose group compared to the two other groups. Survival in the low, median and high dose groups were 4.0, 8.6 and 5.1 months, respectively, with the largest fraction (75%) of immune responders in the median dose group.

Survival is therefore correlated with vaccine dose and immune response in a statistically significant manner. Significantly, after 300 days, only immune responders remained alive. Gemcitabine treatment, which is the standard treatment in many countries, generally results in a median survival of 4.8 - 5.6 months.

"Considering that inoperable pancreatic cancer patients normally are strongly immune suppressed and have a short life expectancy, the results are very encouraging," said Jakob Schmidt, Chief Executive Officer of Pharmexa.

-----------------------------------------

Pharmexa: Presentation at ASCO on June 4, 2007

Summary: The presentation concerns Pharmexa's RAS peptide vaccines in patients with resectable pancreatic cancer

Professor Trond Buanes from Ullevål University Hospital in Norway will on Monday June 4, 2007 present a poster titled "RAS peptide vaccination in resected pancreatic cancer patients - persistence of anti tumour response and long term survival" at ASCO's (American Society of Clinical Oncology) annual cancer meeting.

The data concerns treatment of patients with resectable pancreatic cancer with two peptide vaccines aimed at a specific cancer mutation known as RAS. Rights to these vaccines belong to Pharmexa.

The 2007 ASCO conference will take place from June 1 to June 5 in Chicago, Illinois. It is widely regarded as the most important cancer conference in the world and attracted around 30,000 attendants last year.

Hørsholm, May 29, 2007


Jakob Schmidt
Chief Executive Officer

[BrauchGeld]

Long lasting immune response and survival to RAS vaccine

Summary: Follow-up RAS data presented at ASCO

Professor Trond Buanes today gave a presentation titled "RAS peptide vaccination in resected pancreatic cancer patients - persistence of anti tumour response and long term survival" at ASCO's (American Society of Clinical Oncology) annual cancer meeting.

A follow-up study of 23 resected pancreatic cancer patients immunized in the period from 1995 to 1998 with two different peptide vaccines targeting the RAS mutation found in most instances of pancreatic cancer indicates that a long lasting immune response is possible following immunization with a peptide vaccine. Five patients that showed an immune response to the vaccine were still alive in 2006, i.e. up to 10 years after the operation. Further analysis showed that the immune system in three of these patients still remembered the RAS vaccination.

The RAS vaccines are owned by Pharmexa. In addition, Pharmexa owns a number of other proprietary cancer peptide vaccines, including GV1001 which is in phase III clinical trials.


Hørsholm, June 4, 2007

[BrauchGeld]

Antwort auf Beitrag Nr.: 29.564.767 von BrauchGeld am 31.05.07 22:01:08

Kurs:19,80 D-Kronen = 2,66 €

[cyberhai]

Hallo BrauchGeld,

lass doch den Thread mal unter Pharmexa ablegen, dann findet man diesen einfacher...

Hier gibts News:

http://www.euroinvestor.co.uk/Stock/ShowStockInfo.aspx?Stock…

Gruß Cyberhai

[BrauchGeld]

Die meisten Unternehmen die im ähnlichen bereich wie Dendreon forschen wurden mit runter gezogen aber früher oder später wird sich qualität durchsetzen .

Pharmexa presents data from influenza program

Summary: Pharmexa-Epimmune, the U.S.-based subsidiary of Pharmexa A/S, presents selected data from its influenza vaccine program today at the Influenza Conference entitled, "Options for the Control of Influenza VI," held in Toronto, Ontario, Canada. The data show that a "universal" vaccine designed to induce cell-mediated immune responses can protect transgenic mice against lethal experimental influenza virus challenge.

Pharmexa-Epimmune, the U.S.-based subsidiary of Pharmexa A/S, presented selected data from its influenza vaccine program today at the Influenza Conference entitled, "Options for the Control of Influenza VI," held in Toronto, Ontario, Canada. The company's "universal" vaccine strategy combines the use of multiple technologies developed over the past decade. Specifically, the experimental vaccine protected HLA transgenic mice, which are partially "humanized" against a lethal influenza virus infection.

The vaccine is designed to induce T-cell responses to highly-conserved influenza epitopes that were identified using the proprietary Epitope Identification System (EIS®). Pharmexa-Epimmune's approach is unique to the field where most vaccines are designed with the explicit goal of inducing antibody responses. The goal is to design and test a vaccine that will be protective as a "universal" influenza virus vaccine against both seasonal and pandemic viral strains.

Mark Newman, Ph.D., SVP, Global R&D Laboratories, noted: "These data are very promising and important to us for two reasons. First, we were able to demonstrate protection of the HLA transgenic mice from lethal influenza virus challenge using a vaccine designed to induce only T-cell responses. Second, we were able to demonstrate that the immune system of humans had recognized the selected vaccine epitopes as the result of past exposures to influenza virus and that the HLA transgenic mice responded in a similar manner."


Hørsholm, June 21, 2007